These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8319208)

  • 1. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia.
    el-Beltagi HM; Martens AC; Lelieveld P; Haroun EA; Hagenbeek A
    Cancer Res; 1993 Jul; 53(13):3008-14. PubMed ID: 8319208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of acetyldinaline for treatment of minimal residual disease (MRD): preclinical studies in the BNML rat model for human acute myelocytic leukemia.
    el-Beltagi HM; Martens AC; Dahab GM; Hagenbeek A
    Leukemia; 1993 Nov; 7(11):1795-800. PubMed ID: 8231248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dinaline: a new oral drug against leukemia? Preclinical studies in a relevant rat model for human acute myelocytic leukemia (BNML).
    Hagenbeek A; Weiershausen U; Martens AC
    Leukemia; 1988 Apr; 2(4):226-30. PubMed ID: 3163079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo development of an acetyldinaline resistant subline of the BN rat acute myelocytic leukemia (BNML).
    el-Beltagi HM; Martens AC; Haroun EA; Hagenbeek A
    Leukemia; 1993 Aug; 7(8):1275-80. PubMed ID: 8350629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMSA: in vivo log cell kill for leukemic clonogenic cells versus toxicity for normal hemopoietic stem cells in a rat model for human acute myelocytic leukemia (BNML).
    Hagenbeek A; Martens AC
    Eur J Cancer Clin Oncol; 1986 Oct; 22(10):1255-8. PubMed ID: 3469100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis.
    Volpe DA; LoRusso PM; Foster BJ; Parchment RE
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):89-94. PubMed ID: 15014898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
    Colly LP; Peters WG; Willemze R
    Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).
    Foster BJ; Jones L; Wiegand R; LoRusso PM; Corbett TH
    Invest New Drugs; 1997; 15(3):187-94. PubMed ID: 9387041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cyclophosphamide treatment of acute myelocytic leukemia. Studies in the BNML rat model.
    Hagenbeek A; Martens AC
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):763-9. PubMed ID: 6759141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryopreservation of autologous marrow grafts in acute leukemia: survival of in vivo clonogenic leukemic cells and normal hemopoietic stem cells.
    Hagenbeek A; Martens AC
    Leukemia; 1989 Jul; 3(7):535-7. PubMed ID: 2659904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latent hematopoietic stem cell toxicity associated with protracted drug administration.
    Keyes KA; Segovia JC; Bueren JA; Parchment RE; Albella B
    Exp Hematol; 2001 Mar; 29(3):286-94. PubMed ID: 11274755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical antitumor activity of CI-994.
    LoRusso PM; Demchik L; Foster B; Knight J; Bissery MC; Polin LM; Leopold WR; Corbett TH
    Invest New Drugs; 1996; 14(4):349-56. PubMed ID: 9157069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of doxorubicin for normal hematopoietic and acute myeloid leukemia cells of the rat.
    Sonneveld P; Mulder Ja; van Bekkum DW
    Cancer Chemother Pharmacol; 1981; 5(3):167-73. PubMed ID: 6945921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model.
    Rozemuller H; Rombouts WJ; Touw IP; FitzGerald DJ; Kreitman RJ; Pastan I; Hagenbeek A; Martens AC
    Leukemia; 1996 Nov; 10(11):1796-803. PubMed ID: 8892684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.
    Keyes KA; Albella B; LoRusso PM; Bueren JA; Parchment RE
    Clin Cancer Res; 2000 Jun; 6(6):2474-81. PubMed ID: 10873102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of piperazinedione prior to bone marrow transplantation: studies in a rat model for human acute myelocytic leukemia.
    Hagenbeek A; Martens AC
    Cancer Treat Rep; 1981; 65(7-8):575-82. PubMed ID: 7018679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced tumor load reduction after chemotherapy induced recruitment and synchronization in a slowly growing rat leukemia model (BNML) for human acute myelocytic leukemia.
    Colly LP; van Bekkum DW; Hagenbeek A
    Leuk Res; 1984; 8(6):953-63. PubMed ID: 6595483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
    Vaughan WP; Burke PJ
    Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation.
    Hagenbeek A; Martens AC
    Invest New Drugs; 1984; 2(2):237-43. PubMed ID: 6381383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of high-dose cyclophosphamide in combination with total-body irradiation in the treatment of acute myelocytic leukemia: studies in a relevant rat model.
    Hagenbeek A; Martens AC
    Cancer Res; 1983 Jan; 43(1):408-12. PubMed ID: 6336603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.